Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Correction

Correction: Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts

DOI: 10.1158/1535-7163.MCT-09-1072 Published December 2009
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

In this article (Mol Cancer Ther 2002 1(14):1243-53), published in the December 1, 2002 issue of Molecular Cancer Therapeutics (1), the same images were used to represent multiple treatment conditions in Fig. 4A and B:

  1. The same image was used to represent treatment of L3.6pl (Fig. 4A) and Mia PaCa-2 (Fig. 4B) with 0.6 mg/kg PS-341 as well as treatment of Mia PaCa-2 with 0.8 mg/kg PS-341 (Fig. 4B).

  2. The same image was used to represent treatment of L3.6pl (Fig. 4A) and Mia PaCa-2 (Fig. 4B) with 1.0 mg/kg PS-341.

  3. The same image was used to represent drug control in L3.6pl (Fig. 4A) and Mia PaCa-2 (Fig. 4B).

The authors have corrected the figures and regret their errors. The corrected version is displayed on the previous page.

Corrections for several other articles published in AACR journals containing similar errors have been published. The original articles and their corrections are:

  • Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Dunner K, Jr., Huang P, Abbruzzese JL, McConkey DJ. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res 2005;65:11658-66. doi: 10.1158/0008-5472.CAN-05-2370.

  • Correction in: Cancer Res 2009;69:1695. Published OnlineFirst February 10, 2009. doi: 10.1158/0008-5472.CAN-69-4-COR1.

  • Pino MS, Shrader M, Baker CH, Cognetti F, Xiong HQ, Abbruzzese JL, McConkey DJ. Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines. Cancer Res 2006;66:3802-12. doi: 10.1158/0008-5472.CAN-05-3753.

  • Correction In: Cancer Res 2009;70. Published OnlineFirst December 1, 2009. doi: 10.1158/0008-5472.CAN-09-4221.

  • Nawrocki ST, Sweeney-Gotsch B, Takamori R, McConkey DJ. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2004;3:59-70.

  • Correction in: Mol Cancer Ther 2009;8:479. Published OnlineFirst February 3, 2009. doi: 10.1158/1535-7163.MCT-08-2-COR1.

  • Papageorgiou A, Kamat A, Benedict WF, Dinney C, McConkey DJ. Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Mol Cancer Ther 2006;5:3032-41. doi:10.1158/1535-7163.MCT-05-0474.

  • Correction In: Mol Cancer Ther 2009;8:480. Published OnlineFirst February 3, 2009. doi: 10.1158/1535-7163.MCT-08-2-COR2.

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

The errors in the aforementioned articles were caused in large part by inadequate oversight of data management. In an effort to prevent such errors from occurring in the future, the PI (DJM) has implemented a new data management policy that is designed to limit or eliminate errors in future publications and can be provided upon request (dmcconke@mdanderson.org). The authors note that the conclusions and interpretationof the data in these articles are unaltered by the errors that are now corrected. ARTICLE

  • © 2009 American Association for Cancer Research.

Reference

  1. ↵
    1. Nawrocki ST,
    2. Bruns CJ,
    3. Harbison MT,
    4. Bold RJ,
    5. Gotsch BS,
    6. Abbruzzese JL,
    7. Elliott P,
    8. Adams J,
    9. McConkey DJ
    . Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2002;1:1243–53.
    OpenUrlAbstract/FREE Full Text
Previous
Back to top
Molecular Cancer Therapeutics: 8 (12)
December 2009
Volume 8, Issue 12
  • Table of Contents
  • About the Cover
  • 2009 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Supplement to Vol. 8, Issue 12

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Correction: Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Correction: Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts
Mol Cancer Ther December 1 2009 (8) (12) 3388-3389; DOI: 10.1158/1535-7163.MCT-09-1072

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Correction: Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts
Mol Cancer Ther December 1 2009 (8) (12) 3388-3389; DOI: 10.1158/1535-7163.MCT-09-1072
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Reference
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Correction: In Vitro and In Vivo Synergistic Antitumor Activity of the Combination of BKM120 and Erlotinib in Head and Neck Cancer: Mechanism of Apoptosis and Resistance
  • Correction: An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody–Drug Conjugate for the Treatment of Hormone Receptor–Positive Breast Cancer
  • Correction: Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-negative Breast Cancer
Show more Correction
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement